BlackRock Advisors’s Juniper Pharmaceuticals, Inc. Common Stock JNP Stock Holding History

BlackRock Advisors’s Portfolio JNP Stock Details JNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	$610K	Sell	108,894 -4,590	-4%	-$25.2K	﹤0.01%	2096
2016 Q3	$630K	Sell	113,484 -2,632	-2%	-$17.4K	﹤0.01%	2057
2016 Q2	$814K	Hold	116,116	–	–	﹤0.01%	1856
2016 Q1	$768K	Buy	116,116 +3,068	+3%	+$22.6K	﹤0.01%	1875
2015 Q4	$1.16M	Buy	113,048 +998	+0.9%	+$11.6K	﹤0.01%	1642
2015 Q3	$1.32M	Buy	112,050 +107,374	+2,296%	+$1.19M	﹤0.01%	1535
2015 Q2	$43K	Hold	4,676	–	–	﹤0.01%	3349
2015 Q1	$29K	Hold	4,676	–	–	﹤0.01%	3373
2014 Q4	$26K	Hold	4,676	–	–	﹤0.01%	3441
2014 Q3	$28K	Hold	4,676	–	–	﹤0.01%	3422
2014 Q2	$32K	Hold	4,676	–	–	﹤0.01%	3340
2014 Q1	$34K	Buy	4,676 +2,350	+101%	+$16.2K	﹤0.01%	3317
2013 Q4	$15K	Hold	2,326	–	–	﹤0.01%	3457
2013 Q3	$17K	Buy	+2,326	New	+$15.7K	﹤0.01%	3351

Other funds holding JNP

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Heartland Advisors Milwaukee, Wisconsin $1.96B AUM 28.26% 1-Year Est. Return

JAM

JW Asset Management Miami Beach, Florida $244M AUM 71.51% 1-Year Est. Return

KAM

Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

SCM

Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Algert Global San Francisco, California $6.65B AUM 53.68% 1-Year Est. Return

BlackRock Advisors's JNP Position: Q4 2016 in Review

BlackRock Advisors reduced its Juniper Pharmaceuticals, Inc. Common Stock (JNP) stake by 4% in Q4 2016, selling an estimated $25.2K and leaving 108,894 shares worth $610K. The position accounts for ﹤0.01% of the portfolio, ranked #2096.

BlackRock Advisors first reported a position in JNP in Q3 2013 and has held it in 14 quarters since. The position peaked at $1.32M in Q3 2015. 40 funds tracked by Wall St. Rank hold JNP as of Q4 2016.

BlackRock Advisors held 108,894 shares of Juniper Pharmaceuticals, Inc. Common Stock worth $610K as of Q4 2016.
BlackRock Advisors sold 4,590 Juniper Pharmaceuticals, Inc. Common Stock shares in Q4 2016, an estimated $25.2K.
Juniper Pharmaceuticals, Inc. Common Stock made up ﹤0.01% of BlackRock Advisors's portfolio in Q4 2016, its #2096 holding.
BlackRock Advisors first reported a position in Juniper Pharmaceuticals, Inc. Common Stock in Q3 2013 and has held it in 14 quarters since.
BlackRock Advisors's Juniper Pharmaceuticals, Inc. Common Stock position peaked at $1.32M in Q3 2015.
40 funds tracked by Wall St. Rank held Juniper Pharmaceuticals, Inc. Common Stock as of Q4 2016.

Based on BlackRock Advisors's 13F filing for Q4 2016, filed 10 Feb 2017.